Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024 [Yahoo! Finance]
Eupraxia Pharmaceuticals Inc. (EPRX)
Company Research
Source: Yahoo! Finance
biotechnology company leveraging its proprietary Diffusphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company will present two abstracts at the upcoming Osteoarthritis Research Society International ("OARSI") World Congress 2024. The meeting is being held in Vienna, Austria from April 18-21, 2024 "There is a significant unmet medical need for the treatment of osteoarthritis ("OA") of the knee especially in patients with moderate disease who are years away from a surgical solution," said Dr. James Helliwell , CEO of Eupraxia. "We believe EP-104IAR has the potential to transform the treatment paradigm for this condition by offering a favorable safety profile for chronic therapy, including in diabetic patients who make up one third of OA patients. The Phase 2b SPRINGBOARD study met its primary and key secondary endpoints, showing a clinically and statistically meaningful impact on pain, while also demonstrating that EP
Show less
Read more
Impact Snapshot
Event Time:
EPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPRX alerts
High impacting Eupraxia Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
EPRX
News
- Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024PR Newswire
- Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
- Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory BoardPR Newswire
EPRX
Sec Filings
- 5/15/24 - Form 6-K
- 5/14/24 - Form 6-K
- 5/8/24 - Form 6-K
- EPRX's page on the SEC website